Log In
Print
BCIQ
Print
Print this Print this
 

VAC-3S

  Manage Alerts
Collapse Summary General Information
Company InnaVirVax S.A.
DescriptionHIV gp41 peptide that inhibits reductions in CD4+ T cell count
Molecular Target HIV gp41
Mechanism of Action 
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase II
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV-1 infection
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today